Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Antihistamines and ovarian cancer survival : nationwide cohort study and in vitro cell viability assay. / Verdoodt, Freija; Dehlendorff, Christian; Jäättelä, Marja; Strauss, Robert; Pottegård, Anton; Hallas, Jesper; Friis, Søren; Kjær, Susanne K.
I: Journal of the National Cancer Institute, Bind 112, Nr. 9, 2020, s. 964–967.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antihistamines and ovarian cancer survival
T2 - nationwide cohort study and in vitro cell viability assay
AU - Verdoodt, Freija
AU - Dehlendorff, Christian
AU - Jäättelä, Marja
AU - Strauss, Robert
AU - Pottegård, Anton
AU - Hallas, Jesper
AU - Friis, Søren
AU - Kjær, Susanne K
PY - 2020
Y1 - 2020
N2 - Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.
AB - Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.
U2 - 10.1093/jnci/djz217
DO - 10.1093/jnci/djz217
M3 - Journal article
C2 - 31688928
VL - 112
SP - 964
EP - 967
JO - National Cancer Institute. Journal (Print)
JF - National Cancer Institute. Journal (Print)
SN - 0027-8874
IS - 9
ER -
ID: 237753930